TABLE OF CONTENTS
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF MIDDLE EAST & AFRICA MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET 22
1.4 LIMITATIONS 23
1.5 MARKETS COVERED 23
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 28
2.6 MULTIVARIATE MODELLING 32
2.7 PRODUCTS LIFELINE CURVE 32
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.9 DBMR MARKET POSITION GRID 34
2.10 MARKET APPLICATION COVERAGE GRID 35
2.11 VENDOR SHARE ANALYSIS 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 41
4.1 INTERNATIONAL STANDARDS 41
4.2 REGIONAL STANDARDS 41
4.3 MARKET VIEWPOINT OF KEY OPINION LEADERS 41
4.4 EXPECTATIONS OF FUTURE MARKET SCENARIOS 41
4.5 FINDINGS AND REGIONAL TRENDS 42
4.6 COMPETITIVE GROUPING 43
5 COUNTRY WISE- NO OF PROCEDURES 53
5.1 NORTH AMERICA 54
5.2 EUROPE 55
5.3 ASIA-PACIFIC 56
5.4 SOUTH AMERICA 57
5.5 MIDDLE EAST AND AFRICA 58
6 REGULATION 59
6.1 UNITED STATES 59
6.2 EUROPE 60
6.3 CHINA 61
6.4 AUSTRALIA 61
7 MARKET OVERVIEW 63
7.1 DRIVERS 65
7.1.1 INCREASE IN THE GERIATRIC POPULATION 65
7.1.2 RISE IN INCIDENCE OF GLAUCOMA ACROSS THE WORLD 65
7.1.3 GOVERNMENT INITIATIVES TO INCREASE AWARENESS ABOUT THE PREVENTION OF BLINDNESS 66
7.1.4 GROWTH IN POPULARITY OF MINIMALLY INVASIVE SURGERY ACROSS THE GLOBE 66
7.2 RESTRAINTS 67
7.2.1 INADEQUATE REIMBURSEMENT SCENARIO 67
7.2.2 STRINGENT REGULATIONS FOR MIGS DEVICES 67
7.2.3 HIGH COST OF SURGICAL PROCEDURES 67
7.3 OPPORTUNITIES 68
7.3.1 RAPID TRANSITION FROM GLAUCOMA MEDICATION TO MINIMALLY INVASIVE GLAUCOMA SURGERIES 68
7.3.2 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCT 68
7.4 CHALLENGES 69
7.4.1 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE 69
7.4.2 RISKS ASSOCIATED WITH THE MICRO INVASIVE GLAUCOMA SURGERY 70
8 MIDDLE EAST & AFRICA MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY PRODUCT 71
8.1 OVERVIEW 72
8.2 MIGS STENTS 75
8.3 MIGS SHUNTS 75
8.4 OTHERS 76
9 MIDDLE EAST & AFRICA MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY TARGET 77
9.1 OVERVIEW 78
9.2 TRABECULAR MESHWORK 81
9.3 SUPRACHOROIDAL SPACE 81
9.4 SUBCONJUNCTIVAL FILTRATION 82
9.5 REDUCING AQUEOUS PRODUCTION 83
10 MIDDLE EAST & AFRICA MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY SURGERY TYPE 84
10.1 OVERVIEW 85
10.2 GLAUCOMA IN CONJUNCTION WITH CATARACT 88
10.3 STAND-ALONE GLAUCOMA 88
11 MIDDLE EAST & AFRICA MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY END USER 90
11.1 OVERVIEW 91
11.2 HOSPITAL 94
11.3 OPHTHALMOLOGY CLINICS 94
11.4 AMBULATORY SURGERY CENTERS (ASCS) 95
11.5 OTHERS 96
12 MIDDLE EAST & AFRICA MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY DISTRIBUTION CHANNEL 97
12.1 OVERVIEW 98
12.2 DIRECT TENDER 101
12.3 RETAIL SALES 101
13 MIDDLE EAST & AFRICA MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY REGION 103
13.1 MIDDLE EAST AND AFRICA 104
13.1.1 SOUTH AFRICA 110
13.1.2 SAUDI ARABIA 112
13.1.3 U.A.E. 114
13.1.4 ISRAEL 116
13.1.5 EGYPT 118
13.1.6 REST OF MIDDLE EAST AND AFRICA 120
14 MIDDLE EAST & AFRICA MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET: COMPANY LANDSCAPE 121
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 121
15 SWOT ANALYSIS 122
16 COMPANY PROFILE 123
16.1 GLAUKOS CORPORATION 123
16.1.1 COMPANY SNAPSHOT 123
16.1.2 REVENUE ANALYSIS 123
16.1.3 COMPANY SHARE ANALYSIS 124
16.1.4 PRODUCT PORTFOLIO 124
16.1.4.1 RECENT DEVELOPMENT 124
16.2 ALCON INC. 125
16.2.1 COMPANY SNAPSHOT 125
16.2.2 REVENUE ANALYSIS 125
16.2.3 COMPANY SHARE ANALYSIS 126
16.2.4 PRODUCT PORTFOLIO 126
16.2.4.1 RECENT DEVELOPMENTS 127
16.3 ABBVIE INC. 128
16.3.1 COMPANY SNAPSHOT 128
16.3.2 REVENUE ANALYSIS 128
16.3.3 COMPANY SHARE ANALYSIS 129
16.3.4 PRODUCT PORTFOLIO 129
16.3.4.1 RECENT DEVELOPMENT 129
16.4 JOHNSON & JOHNSON SURGICAL VISION, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON) 130
16.4.1 COMPANY SNAPSHOT 130
16.4.2 REVENUE ANALYSIS 130
16.4.3 COMPANY SHARE ANALYSIS 131
16.4.4 PRODUCT PORTFOLIO 131
16.4.4.1 RECENT DEVELOPMENT 131
16.5 SANTEN PHARMACEUTICAL CO., LTD. 132
16.5.1 COMPANY SNAPSHOT 132
16.5.2 REVENUE ANALYSIS 132
16.5.3 COMPANY SHARE ANALYSIS 133
16.5.4 PRODUCT PORTFOLIO 133
16.5.4.1 RECENT DEVELOPMENTS 133
16.6 BELKIN VISION, ISRAEL 135
16.6.1 COMPANY SNAPSHOT 135
16.6.2 PRODUCT PORTFOLIO 135
16.6.3 RECENT DEVELOPMENT 135
16.7 BVI 136
16.7.1 COMPANY SNAPSHOT 136
16.7.2 PRODUCT PORTFOLIO 136
16.7.2.1 RECENT DEVELOPMENTS 137
16.8 ELLEX INC. 138
16.8.1 COMPANY SNAPSHOT 138
16.8.2 PRODUCT PORTFOLIO 138
16.8.2.1 RECENT DEVELOPMENTS 138
16.9 IOPTIMA 139
16.9.1 COMPANY SNAPSHOT 139
16.9.2 PRODUCT PORTFOLIO 139
16.9.3 RECENT DEVELOPMENT 139
16.10 MICROSURGICAL TECHNOLOGY. (A SUBSIDIARY OF HALMA PLC) 140
16.10.1 COMPANY SNAPSHOT 140
16.10.2 PRODUCT PORTFOLIO 140
16.10.2.1 RECENT DEVELOPMENT 140
16.11 NEW WORLD MEDICAL, INC. 141
16.11.1 COMPANY SNAPSHOT 141
16.11.2 PRODUCT PORTFOLIO 141
16.11.2.1 RECENT DEVELOPMENTS 141
16.12 NOVA EYE MEDICAL LIMITED 142
16.12.1 COMPANY SNAPSHOT 142
16.12.2 REVENUE ANALYSIS 142
16.12.3 PRODUCT PORTFOLIO 143
16.12.3.1 RECENT DEVELOPMENTS 143
16.13 SIGHT SCIENCES. 144
16.13.1 COMPANY SNAPSHOT 144
16.13.2 REVENUE ANALYSIS 144
16.13.3 PRODUCT PORTFOLIO 145
16.13.3.1 RECENT DEVELOPMENTS 145
17 QUESTIONNAIRE 147
18 RELATED REPORTS 149

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.